1.Comparison of the Facelift Incision versus V-Shaped Incision for Parotidectomy.
Ji Hye KWAK ; Jae Young LEE ; Gil Joon LEE ; Jin Ho SOHN ; Dongbin AHN
Korean Journal of Otolaryngology - Head and Neck Surgery 2019;62(1):43-48
BACKGROUND AND OBJECTIVES: The purpose of the present study was to compare the results of V-shaped and modified facelift incisions for parotidectomy. SUBJECTS AND METHOD: Ninety parotidectomy patients who underwent V-shaped and modified facelift incisions from 2014 to 2018 were enrolled in this study. Patient characteristics, tumor profiles, surgical outcomes, postoperative complications, and cosmetic results were assessed for the V-shaped (n=20) and modified facelift (n=70) incision groups. RESULTS: The tumor size was significantly larger in the modified facelift incision group than in the V-shaped incision group (2.6 cm vs. 1.9 cm, p < 0.001). There were no significant differences between the two groups regarding other baseline tumor characteristics, operating time, and postoperative complications. Although the results of Vancouver Scar Scale was similar in both groups, the V-shaped incision group showed higher subjective scar satisfaction scores than the modified facelift incision group (9.3 vs. 8.6, p=0.001). CONCLUSION: The results suggest that the V-shaped incision is feasible and can provide better subjective scar satisfaction in selected parotidectomy patients without increased complications.
Cicatrix
;
Humans
;
Methods
;
Parotid Neoplasms
;
Postoperative Complications
;
Rhytidoplasty*
2.Absence of neutralizing activity in serum 1 year after successful treatment with antivirals and recovery from MERS in South Korea.
Jun Yong CHOI ; Jin Ok OH ; Jin Young AHN ; Heun CHOI ; Jung Ho KIM ; Hye SEONG ; Su Jin JEONG ; Nam Su KU ; Joon Sup YEOM ; Jae Phil CHOI
Clinical and Experimental Vaccine Research 2019;8(1):86-88
We evaluated the neutralizing activity in serum from three patients >1 year after recovery from Middle East respiratory syndrome (MERS) associated with mild pneumonia treated with antivirals during the MERS outbreak in South Korea at 2015. The neutralizing activity in serum was measured by pseudovirus inhibition assays. Three-fold diluted serum of subjects showed only 9.7%, 10.3%, and 2.2% reductions in relative light units. So, significant neutralizing activity was not demonstrated in any sera of three patients with mild pneumonia >1 year after being successfully treated with antiviral agents and recovering from MERS coronavirus infection.
Antibodies, Neutralizing
;
Antiviral Agents*
;
Coronavirus Infections
;
Humans
;
Korea*
;
Middle East Respiratory Syndrome Coronavirus
;
Pneumonia
3.Remifentanil promotes osteoblastogenesis by upregulating Runx2/osterix expression in preosteoblastic C2C12 cells
Ji Young YOON ; Tae Sung KIM ; Ji Hye AHN ; Ji Uk YOON ; Hyung Joon KIM ; Eun Jung KIM
Journal of Dental Anesthesia and Pain Medicine 2019;19(2):91-99
BACKGROUND: The imbalance between osteoblasts and osteoclasts can lead to pathological conditions such as osteoporosis. It has been reported that opioid adversely affect the skeletal system, but it is inconsistent. Remifentanil is currently used as an adjuvant analgesic drug in general anesthesia and sedation. The aim of the present study was to investigate the effect of remifentanil on the osteoblast differentiation and mechanism involved in this effect. METHODS: The C2C12 cells (mouse pluripotent mesenchymal cell line) were used as preosteoblast. Osteoblastic differentiation potency was determined by alkaline phosphatase (ALP) staining. C2C12 cell migration by remifentanil was evaluated using Boyden chamber migration assay. The expression of Runx2 and osterix was evaluated by RT-PCT and western blot analysis to investigate the mechanism involved in remifentanil-mediated osteoblast differentiation. RESULTS: ALP staining showed that remifentanil increased significantly osteoblast differentiation. In Boyden chamber migration assay, C2C12 cell migration was increased by remifentanil. RT-PCR and western blot analysis showed that the expression of Runx2 and osterix was upregulated by remifentanil. CONCLUSIONS: We demonstrated that remifentanil increased osteoblast differentiation in vitro by upregulation of Runx2 and osterix expression. Therefore, remifentanil has the potential for assisting with bone formation and bone healing.
Alkaline Phosphatase
;
Anesthesia, General
;
Blotting, Western
;
Cell Movement
;
In Vitro Techniques
;
Osteoblasts
;
Osteoclasts
;
Osteogenesis
;
Osteoporosis
;
Up-Regulation
4.Ethanol Ablation of the Thyroid Nodules: 2018 Consensus Statement by the Korean Society of Thyroid Radiology
Soo Yeon HAHN ; Jung Hee SHIN ; Dong Gyu NA ; Eun Joo HA ; Hye Shin AHN ; Hyun Kyung LIM ; Jeong Hyun LEE ; Jeong Seon PARK ; Ji hoon KIM ; Jin Yong SUNG ; Joon Hyung LEE ; Jung Hwan BAEK ; Jung Hyun YOON ; Jung Suk SIM ; Kwang Hwi LEE ; Seon Mi BAEK ; So Lyung JUNG ; Yeo Koon KIM ; Yoon Jung CHOI ;
Korean Journal of Radiology 2019;20(4):609-620
Minimally invasive treatment of symptomatic thyroid nodules is now commonplace. Ethanol ablation (EA) of thyroid cystic nodules has been performed since the 1990s, but there is no global consensus or guideline. Although various limitations of EA have been described, recommendations for practical application are necessary. Therefore, the Task Force Committee of the Korean Society of Thyroid Radiology initiated the present consensus statement and here we provide recommendations for the role of EA in the management of symptomatic thyroid nodules. These recommendations are based on evidence to date from the literature and expert opinion.
Advisory Committees
;
Consensus
;
Ethanol
;
Expert Testimony
;
Thyroid Gland
;
Thyroid Neoplasms
;
Thyroid Nodule
5.Rapid Staining Using the Shorr Method for Intraoperative Peritoneal Washing Cytology in Advanced Gastric Cancer: a Pilot Study from a Single Institution
Sang Yong SON ; Hai Young CHOI ; Yoontaek LEE ; Young Suk PARK ; Dong Joon SHIN ; Aung Myint OO ; Do Hyun JUNG ; Sang Hoon AHN ; Do Joong PARK ; Hye Seung LEE ; Hyung Ho KIM
Journal of Gastric Cancer 2019;19(2):173-182
PURPOSE: Intraoperative peritoneal washing cytology (PWC) is used to determine treatment strategies for gastric cancer with suspected serosal invasion. However, a standard staining method for intraoperative PWC remains to be established. We evaluated the feasibility of a rapid and simple staining method using Shorr's stain for intraoperative PWC in advanced gastric cancer. MATERIALS AND METHODS: Between November 2012 and December 2014, 77 patients with clinical T3 or higher gastric cancer were enrolled. The sensitivity, specificity, and concordance between the Shorr staining method and conventional Papanicolaou (Pap) staining with carcinoembryonic antigen (CEA) immunohistochemistry (IHC) were analyzed. RESULTS: Intraoperative PWC was performed laparoscopically in 69 patients (89.6%). The average time of the procedure was 8.3 minutes, and the average amount of aspirated fluids was 83.3 mL. The average time for Shorr staining and pathologic review was 21.0 minutes. Of the 77 patients, 16 (20.7%) had positive cytology and 7 (9.1%) showed atypical findings; sensitivity and specificity were 73.6% and 98.2% for the Shorr method, and 78.9% and 98.2% for the Pap method with CEA IHC, respectively. Concordance of diagnosis between the 2 methods was observed in 90.9% of cases (weighted κ statistic=0.875) and most disagreements in diagnoses occurred in atypical findings (6/7). In overall survival, there was no significant difference in C-index between the 2 methods (0.459 in Shorr method vs. 0.458 in Pap with CEA IHC method, P=0.987). CONCLUSIONS: Shorr staining could be a rapid and reliable method for intraoperative PWC in advanced gastric cancer.
Carcinoembryonic Antigen
;
Diagnosis
;
Humans
;
Immunohistochemistry
;
Laparoscopy
;
Methods
;
Pilot Projects
;
Sensitivity and Specificity
;
Stomach Neoplasms
6.2019 Consensus Korean Diagnostic Guidelines to Define Severity Classification and Treatment Refractoriness for Atopic Dermatitis: Objective and Subjective Assessment of Severity
Jung Eun KIM ; Min Kyung SHIN ; Gyeong Hun PARK ; Un Ha LEE ; Ji Hyun LEE ; Tae Young HAN ; Hyun Chang KOH ; Yong Hyun JANG ; Hye One KIM ; Chan Ho NA ; Bark Lynn LEW ; Ji Young AHN ; Chang Ook PARK ; Young Joon SEO ; Yang Won LEE ; Sang Wook SOHN ; Young Lip PARK
Annals of Dermatology 2019;31(6):654-661
BACKGROUND: Systemic immunomodulatory treatment is actively recommended in the treatment for moderate to severe atopic dermatitis (AD) patients. However, consensus criteria for the classification of AD severity or treatment refractoriness have not been established yet. OBJECTIVE: To establish consensus criteria on the definition of severity classification and treatment refractoriness of AD to provide a basis for proper treatment strategy. METHODS: The Korean Atopic Dermatitis Association (KADA) comprised a task force team to establish a definition of moderate to severe AD. A draft of definition of moderate to severe AD was made on the basis of evidence. The recommendation was confirmed by KADA members through a web-based survey. RESULTS: KADA approved that AD with 16≤eczema area and severity index (EASI)<23 should be basically defined as moderate AD whereas AD with EASI score ≥23 should be considered as severe AD. They agreed that it would be reasonable to raise the severity level if patient's daytime or nighttime pruritus numerical rating scale is equal to or higher than 7 (≥7) or dermatology life quality index score exceeds 10. AD patients who do not reach EASI 50 after appropriate treatment for three months should be considered as a non-responder. Patients with recurrence (EASI ≥16) within three months after cessation of treatment should be considered as a recurrent AD. CONCLUSION: KADA built a consensus of definition of moderate and severe AD and treatment-refractoriness. These guidelines are expected to help physicians determine proper treatment options in need.
Advisory Committees
;
Classification
;
Consensus
;
Dermatitis, Atopic
;
Dermatology
;
Diagnosis
;
Humans
;
Pruritus
;
Quality of Life
;
Recurrence
;
Treatment Failure
;
Withholding Treatment
7.Oxaliplatin-induced Peripheral Neuropathy, Symptoms, Distress and Quality of Life among Korean Patients with Gastrointestinal Cancer
Hye Jeong JUNG ; Soo jung AHN ; Yoo Ri YANG ; Kyoung A KIM ; Sang Joon SHIN ; Min Kyu JUNG ; Sang Hui CHU
Asian Oncology Nursing 2019;19(4):204-213
PURPOSE: This study was conducted to identify the level of oxaliplatin-induced peripheral neuropathy (OIPN), symptoms, distress, and quality of life (QoL) in gastrointestinal (GI) cancer patients and to identify the factors influencing QoL.METHODS: A total of 123 patients were recruited for this cross-sectional study. Surveys used were the Therapy-Induced Neuropathy Assessment Scale (TNAS) for OIPN, the MD Anderson Symptom Inventory (MDASI-GI) for general symptoms associated with gastrointestinal cancer and its treatment, a distress thermometer, and the Euro Quality of Life Questionnaire 5-Dimensional Classification (EQ-5D) for QoL.RESULTS: The patients were classified into three groups based on their treatment completion time (current, completed less than one year ago, completed more than one year ago). The scores of MDASI-GI and distress were significantly lower in patients who had completed chemotherapy compared to those who were undergoing treatment (p=.04 and .02 respectively). However, TNAS score was significantly higher in patients who completed chemotherapy less than one year ago than the other two groups (p=.001). In multivariate regression models, the OIPN and distress or general symptoms were identified as factors associated with QoL.CONCLUSION: In this study, we identified the symptoms that are factors related to the QoL in patients with GI cancer. In particular, the symptoms of OIPN are reported at significantly increased levels for patients who have finished chemotherapy less than one year ago, so efforts to prevent and manage the symptoms of OIPN are needed in this timeframe. To improve QoL of patients with GI cancer, continuous attention and care are required not only during the treatment of cancer but also after the completion of treatment.
Classification
;
Cross-Sectional Studies
;
Drug Therapy
;
Gastrointestinal Neoplasms
;
Humans
;
Peripheral Nervous System Diseases
;
Quality of Life
;
Thermometers
8.The 2016 WHO versus 2008 WHO Criteria for the Diagnosis of Chronic Myelomonocytic Leukemia.
Yeonsook MOON ; Mi Hyang KIM ; Hye Ryoun KIM ; Jeong Yeal AHN ; Jungwon HUH ; Ji Young HUH ; Jae Ho HAN ; Joon Seong PARK ; Sung Ran CHO
Annals of Laboratory Medicine 2018;38(5):481-483
The 2016 WHO diagnostic criteria for chronic myelomonocytic leukemia (CMML) require both absolute and relative monocytosis (≥1×10⁹/L and ≥10% of white blood cell counts) in peripheral blood. Moreover, myeloproliferative neoplasm (MPN) features in bone marrow and/or MPN-associated mutations tend to support MPN with monocytosis rather than CMML. We assessed the impact of the 2016 WHO criteria on CMML diagnosis, compared with the 2008 WHO criteria, through a retrospective review of the medical records of 38 CMML patients diagnosed according to the 2008 WHO classification. Application of the 2016 WHO criteria resulted in the exclusion of three (8%) patients who did not fulfill the relative monocytosis criterion and eight (21%) patients with an MPN-associated mutation. These 11 patients formed the 2016 WHO others group; the remaining 27 formed the 2016 WHO CMML group. The significant difference in the platelet count and monocyte percentage between the two groups indicated that the 2016 WHO criteria lead to a more homogenous and improved definition of CMML compared with the 2008 WHO criteria, which may have led to over-diagnosis of CMML. More widespread use of molecular tests and more sophisticated clinical and morphological evaluations are necessary to diagnose CMML accurately.
Bone Marrow
;
Classification
;
Diagnosis*
;
Humans
;
Leukemia, Myelomonocytic, Chronic*
;
Leukocytes
;
Medical Records
;
Monocytes
;
Platelet Count
;
Retrospective Studies
9.Bozola Flap for Oral Cavity Reconstruction in Patients with Tongue Cancer.
Ji Hye KWAK ; Gil Joon LEE ; Jin Ho SOHN ; Dongbin AHN
Korean Journal of Otolaryngology - Head and Neck Surgery 2018;61(11):605-610
BACKGROUND AND OBJECTIVES: The purpose of the present study was to evaluate the usefulness of a posterior-based buccinator myomucosal flap (the Bozola flap) for the reconstruction of oral cavity defects after tongue cancer resection. SUBJECTS AND METHOD: Fifteen patients who underwent from 2014 to 2016 reconstruction of the oral cavity with a Bozola flap after surgical management of tongue cancer were enrolled in the study. Patient characteristics, surgical outcomes, and complications associated with the Bozola flap were evaluated. RESULTS: The flap was successfully harvested and transferred in all patients. The mean flap harvesting time was 25.3 min. The donor site was closed primarily in 14 patients, and a buccal fat pad flap was used in one patient. Although partial necrosis of the flap occurred in two patients, no other major complications were noted. CONCLUSION: The results of this study demonstrate that the Bozola flap is a good option for reconstruction of moderate sized oral cavity defects in tongue cancer patients.
Adipose Tissue
;
Humans
;
Methods
;
Mouth Mucosa
;
Mouth*
;
Necrosis
;
Reconstructive Surgical Procedures
;
Tissue Donors
;
Tongue Neoplasms*
;
Tongue*
10.Treatment of Atopic Dermatitis.
Tae Young HAN ; Chan Ho NA ; Ji Hyun LEE ; Hye One KIM ; Chang Ook PARK ; Young Joon SEO ; Sang Wook SON ; Min Kyung SHIN ; Ji Young AHN ; Yang Won LEE ; Yong Hyun JANG ; Young Lip PARK ; Bark Lynn LEW
Korean Journal of Dermatology 2018;56(10):581-593
Atopic dermatitis (AD) is a common, chronic, relapsing, inflammatory skin disease that affects both children and adults. AD is the cause of considerable morbidity including severe pruritus and impaired quality of life. Treatments for active disease include avoidance of triggering factors, barrier repair, topical medications including topical corticosteroids (TCs) and topical calcineurin inhibitors (TCIs), phototherapy, antibacterial agents, and systemic immunosuppressants including cyclosporine. Until recently, the only Food and Drug Administration (FDA)-approved systemic treatment options for patients with moderate-to-severe AD were steroids and cyclosporine. Systemic steroids are not recommended by current guidelines and are commonly associated with disease rebound. Instead, clinicians choose from several off-label immunosuppressants. In 2018, the Korean FDA approved dupilumab for adults with moderate-to-severe AD whose disease is not adequately controlled with topical therapies. The implementation of treatment guidelines for AD is challenging. Herein, we review the several treatment modalities for AD and recommend a treatment algorithm.
Adrenal Cortex Hormones
;
Adult
;
Anti-Bacterial Agents
;
Calcineurin Inhibitors
;
Child
;
Cyclosporine
;
Dermatitis, Atopic*
;
Humans
;
Immunosuppressive Agents
;
Phototherapy
;
Pruritus
;
Quality of Life
;
Skin Diseases
;
Steroids
;
United States Food and Drug Administration

Result Analysis
Print
Save
E-mail